Company · FULC
Fulcrum Therapeutics, Inc.
Nasdaq's symbol directory lists FULC on Nasdaq as “Fulcrum Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 5 occasions ($1.5M); insiders sold on 1 occasion ($66K); 13 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Kevin Tang bought $1.5M
- Alan Ezekowitz sold $66K
Every trade (6)
- BUYKevin Tang bought $179K
- BUYKevin Tang bought $415K
- BUYKevin Tang bought $382K
- BUYKevin Tang bought $463K
- BUYKevin Tang bought $46K
- SELLAlan Ezekowitz sold $66K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Nantahala Capital Management, LLC 8.62%
- Montanova Capital, LLC 0%
- BANK OF AMERICA CORP /DE/ 1.5%
- BlackRock Portfolio Management LLC 8.1%
- Nantahala Capital Management, LLC 8.22%
- Montanova Capital, LLC 5.5%
- RA Capital Management, L.P. 0%
- TCG Crossover GP II, LLC 0%
- BANK OF AMERICA CORP /DE/ 6.7%
- BlackRock, Inc. 7.2%
- BlackRock Portfolio Management LLC 6%
- TANG CAPITAL MANAGEMENT LLC 10.4%
- TANG CAPITAL MANAGEMENT LLC 8.2%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Other events Nov 12, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.